Skip to main content

Table 2 Participants’ characteristics

From: Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile

  Definition 1
(n = 318)
Definition 2
(n = 313*)
Definition 3
(n = 318)
Aβ- Low burden Aβ+   Aβ- Low burden Aβ+   Aβ- Low burden Aβ+  
CSF- CL < 30
(n = 205, 64.5%)
CSF+ CL < 30
(n = 88, 27.7%)
CSF+ CL > 30
(n = 25, 7.86%)
P value CSF- VR-
(n = 202, 64.5%)
CSF+ VR-
(n = 72, 23.0%)
CSF+ VR+
(n = 39, 12.5%)
P value CL < 20
(n = 281, 88.4%)
20 - 40 CL
(n = 18, 5.66%)
CL > 40
(n = 19, 6.0%)
P value
Age, years 60.5 (4.32) 61.2 (5.14) 65.7 (2.64)1,2 <0.0001 60.5 (4.34) 60.8 (5.23) 64.9 (3.41)1,2 <0.0001 60.6 (4.61) 64.0 (3.53)3 65.5 (2.89)1 <0.0001
Female, n (%) 133 (64.9) 48 (54.5) 18 (72.0) 0.12 131 (64.9) 40 (55.6) 24 (61.5) 0.37 175 (62.3) 11 (61.1) 13 (68.4) 0.86
Education, years 13.4 (3.44) 13.7 (3.44) 12.2 (3.95) 0.19 13.6 (3.40) 13.5 (3.30) 12.5 (3.89) 0.20 13.5 (3.42) 13.3 (3.85) 12.5 (3.99) 0.53
MMSE 29.1 (0.98) 29.4 (0.91) 28.9 (1.09) 0.10 29.1 (0.95) 29.3 (0.90) 29.0 (1.09) 0.25 29.2 (0.95) 29.2 (1.04) 29.1 (1.03) 0.90
APOE-ε4 carriers, n (%) 85 (41.5) 70 (79.5)1 17 (68.0) <0.0001 82 (40.6) 57 (79.2)1 28 (71.8)3 <0.0001 145 (51.6) 13 (72.2) 14 (73.7) 0.049
Centiloid (CL) −4.58 (6.51) 7.06 (10.2)1 50.9 (12.6)1,2 <0.0001 −4.66 (6.51) 5.52 (9.40)1 36.3 (21.7)1,2 <0.0001 −2.17 (7.99) 28.2 (6.10)1 55.6 (10.6)1,2 <0.0001
CSF Aβ42/40 0.087 (0.009) 0.055 (0.010)1 0.040 (0.008)1,2 <0.0001 0.086 (0.009) 0.056 (0.011)1 0.045 (0.011)1,2 <0.0001 0.078 (0.016) 0.045 (0.010)1 0.041 (0.008)1 <0.0001
  1. Data are expressed as mean (M) and standard deviation (SD) or number of participants (n) and percentage (%), as appropriate. One-way ANOVA followed by Tukey corrected post hoc pairwise comparisons was used to compared age, education, and MMSE performance and Pearson’s chi-squared test to compare sex and APOE-ε4 status between groups within each definition. CSF Aβ42/40 and CL were compared with an ANCOVA adjusted by age and sex followed by Tukey corrected post hoc pairwise comparison. The P values indicated in the last column refer to the group main effect. Significant P values are marked in bold. “Low burden” refers to “Low burden of Ab pathology”. Abbreviations: amyloid-β, CL Centiloid, CSF cerebrospinal fluid, MMSE mini-mental state examination, VR visual read
  2. *In definition 2, we included 313 participants because 2 participants did not have Aβ PET visual read assessment available and 3 additional participants had a discrepant CSF and visual read assessment (negative CSF Aβ42/40 ratio but positive visual read). Participants with this biomarker profile do not fall in any of the definition 2 categories
  3. 1P < 0.0001 vs Aβ- group
  4. 2P < 0.0001 vs low burden group
  5. 3P < 0.01 vs Aβ- group